Gilead Sciences Inc. (GILD)

Balance Sheet: Liabilities and Stockholders’ Equity

Difficulty: Beginner

The balance sheet provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Gilead Sciences Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

		Dec 31, 2018		Dec 31, 2017		Dec 31, 2016		Dec 31, 2015		Dec 31, 2014
	Accounts payable
	Accrued government and other rebates
	Compensation and employee benefits
	Accrued payment for marketing-related rights acquired from Japan Tobacco
	Income taxes payable
	Other accrued expenses
	Other accrued liabilities
	Current portion of long-term debt and other obligations, net
	Current liabilities
	Long-term debt, net, excluding current portion
	Long-term income taxes payable
	Other long-term obligations
	Long-term liabilities
	Total liabilities
	Equity component of currently redeemable convertible notes
	Preferred stock, par value $0.001 per share; none outstanding
	Common stock, par value $0.001 per share
	Additional paid-in capital
	Accumulated other comprehensive income
	Retained earnings
	Total Gilead stockholders’ equity
	Noncontrolling interest
	Total stockholders’ equity
	Total liabilities and stockholders’ equity

Based on: 10-K (filing date: 2019-02-26), 10-K (filing date: 2018-02-27), 10-K (filing date: 2017-02-27), 10-K (filing date: 2016-02-24), 10-K (filing date: 2015-02-25).

Balance sheet item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Gilead Sciences Inc.’s current liabilities increased from 2016 to 2017 but then slightly declined from 2017 to 2018.
Long-term liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Gilead Sciences Inc.’s long-term liabilities increased from 2016 to 2017 but then slightly declined from 2017 to 2018 not reaching 2016 level.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Gilead Sciences Inc.’s total liabilities increased from 2016 to 2017 but then slightly declined from 2017 to 2018 not reaching 2016 level.
Total Gilead stockholders’ equity	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Gilead Sciences Inc.’s total Gilead stockholders’ equity increased from 2016 to 2017 and from 2017 to 2018.

	Gilead Sciences Inc.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality